(Q36859714)

English

Defining the optimal treatment strategy for localized prostate cancer patients: a survey of ongoing studies at the National Cancer Institute of Canada Clinical Trials Group

scientific article published on August 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Defining the optimal treatment strategy for localized prostate cancer patients: a survey of ongoing studies at the National Cancer Institute of Canada Clinical Trials Group (English)

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

1 reference

based on heuristic

inferred from title

author name string

W R Parulekar

1

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

M McKenzie

2

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

K N Chi

3

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

L Klotz

4

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

C Catton

5

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

M Brundage

6

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

K Ding

7

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

A Hiltz

8

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

R Meyer

9

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

F Saad

10

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 August 2008

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Current Oncology

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

15

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

4

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

179-184

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

copyright license

Creative Commons Attribution 4.0 International

1 August 2008

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Active surveillance for favorable risk prostate cancer: rationale, risks, and results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2528309

29 September 2017

Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2528309

29 September 2017

Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2528309

29 September 2017

Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2528309

29 September 2017

20-year outcomes following conservative management of clinically localized prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2528309

29 September 2017

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2528309

29 September 2017

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2528309

29 September 2017

Current opinion on adjuvant and salvage treatment after radical prostatectomy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2528309

29 September 2017

Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2528309

29 September 2017

Single-agent chemotherapy with docetaxel significantly reduces PSA levels in patients with high-grade localized prostate cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2528309

27 June 2018

Results of conservative management of clinically localized prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2528309

27 June 2018

Docetaxel followed by hormone therapy in men experiencing increasing prostate-specific antigen after primary local treatments for prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2528309

4 September 2018

Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2528309

4 September 2018

Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2528309

4 September 2018

Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2528309

4 September 2018

Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2528309

4 September 2018

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2528309

4 September 2018

Overdiagnosis Due to Prostate-Specific Antigen Screening: Lessons From U.S. Prostate Cancer Incidence Trends

1 reference

https://pubmed.ncbi.nlm.nih.gov/18769611

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/18769611

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant and salvage treatment after radical prostatectomy: current practice in the UK

1 reference

https://pubmed.ncbi.nlm.nih.gov/18769611

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911)

1 reference

https://pubmed.ncbi.nlm.nih.gov/18769611

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden

1 reference

https://pubmed.ncbi.nlm.nih.gov/18769611

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bcl2 is the guardian of microtubule integrity

1 reference

https://pubmed.ncbi.nlm.nih.gov/18769611

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3747/CO.V15I4.257

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36859714&oldid=2087725793"